Yan Jing, Zhou Xijian, Pan Dejian
Department of Oncology, The 904 Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army, Wuxi, Jiangsu, 214044, PR China.
Department of Oncology, The 904 Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army, Wuxi, Jiangsu, 214044, PR China.
Lung Cancer. 2020 Sep;147:26-29. doi: 10.1016/j.lungcan.2020.06.026. Epub 2020 Jun 24.
The FAM179A gene has recently been screened as a new fusion partner fusing to the anaplastic lymphoma kinase gene (ALK) in plasma cell-free DNA (cfDNA) of patients with non-small-cell lung cancer (NSCLC). However, the response of patients with NSCLC harboring the FAM179A-ALK fusion to ALK inhibitors remains unknown. In this study we report a novel FAM179A-ALK rearrangement variant (F1, A19) identified by next-generation sequencing in an NSCLC patient with multiple brain metastases (M1c). This patient responded sensitively to lorlatinib as evaluated by brain MRI and chest CT, followed up using plasma cfDNA. The conclusion is that we found a novel FAM179A-ALK rearrangement variant (F1, A19) and provided evidence of its sensitivity to ALK inhibitors.
FAM179A基因最近在非小细胞肺癌（NSCLC）患者的游离血浆DNA（cfDNA）中被筛选为一种新的与间变性淋巴瘤激酶基因（ALK）融合的融合伴侣。然而，携带FAM179A-ALK融合的NSCLC患者对ALK抑制剂的反应仍然未知。在本研究中，我们报告了通过下一代测序在一名患有多发脑转移（M1c）的NSCLC患者中鉴定出的一种新型FAM179A-ALK重排变体（F1，A19）。通过脑部MRI和胸部CT评估，该患者对劳拉替尼敏感，随后使用血浆cfDNA进行随访。结论是，我们发现了一种新型FAM179A-ALK重排变体（F1，A19），并提供了其对ALK抑制剂敏感性的证据。
